A B S T R A C T Basic lipophilic drugs such as propranolol and lidocaine are strongly bound by a1-acid glycoprotein, also called orosomucoid. Although the liver is known to rapidly clear plasma protein-bound propranolol or lidocaine, it is generally regarded that peripheral tissues, such as brain or heart, are only exposed to the small fraction of drug that is free or dialyzable in vitro. The "free drug" hypothesis is subjected to direct empiric testing in the present studies using human sera and an in vivo rat brain paradigm.
the in vivo rat brain paradigm used in the present investigations is capable of confirming, when possible, predictions made by the "free drug" hypothesis.
These data suggest that the amount of circulating propranolol or lidocaine that is available for transport into a peripheral tissue such as brain is not restricted to the free (dialyzable) moiety but includes the much larger globulin-bound fraction. Therefore, existing pharmacokinetic models should be expanded to account for the transport of protein-bound drugs into peripheral tissues similar to what is known to occur in liver.
INTRODUCTION
Basic lipophilic drugs such as propranolol or lidocaine are widely used in clinical practice (1, 2) . The pharmacologic effect of these agents is proportional to the plasma total drug concentration (3, 4) . The clinical interpretation of plasma drug levels is complicated by the fact that many basic lipophilic drugs are bound by a plasma globulin, orosomucoid, i.e., a,-acid glycoprotein (5) (6) (7) . Orosomucoid is an acute-phase reactant and serum levels of this protein rise severalfold in a variety of inflammatory illnesses (8) . For example, the binding of propranolol (and chlorpromazine, another basic lipophilic drug) by orosomucoid is increased in rheumatoid arthritis, Crohn's disease, chronic renal failure, and hyperthyroidism (5, 9) . Orosomucoid binding of lidocaine increases after myocardial infarction, due to increased orosomucoid levels (10) . Plasma binding of quinidine, another basic lipophilic drug, increases precipitously in the postoperative period in parallel with increases in plasma orosomucoid concentrations (11) . Conversely, high estrogen states, e.g., oral contraceptives, pregnancy, cirrhosis, and the fetal state, are associated with low orosomucoid con-centrations and with decreased plasma protein binding of propranolol (12, 13) .
Protein-bound propranolol is known to be readily available for entry into liver (14) and this accounts for the large first pass effect by liver on the systemic bioavailability of drug (15) . Although it is widely recognized that protein-bound drug is transported into liver (14) , it is still generally regarded that only free, nonprotein bound drug is available for entry into peripheral tissues such as the heart and brain (16, 17) . This latter view is supported by the observation that the cardiac effect of propranolol correlates well with the free drug in serum (18) . However, a demonstration of the correlation between two parameters does not prove a causal relationship and does not provide information regarding the pathway by which circulating propranolol reaches receptor sites in peripheral tissues.
A critical examination of the free drug hypothesis for peripheral tissues has yet to be undertaken, owing to the lack of a suitable methodology to empirically test the hypothesis (19) . In these studies, we test the free drug hypothesis with studies of propranolol and lidocaine transport into brain, by a method used previously by us to test the free hormone hypothesis (20) (21) (22) . The method measures the effects of plasma protein on the transport of hormones and drugs through the rat brain endothelial wall, i.e., the blood-brain barrier (BBB).' Since plasma proteins do not cross the BBB, the inhibition of BBB transport of ligand by the plasma protein reflects in vivo binding of ligand within the brain capillary lumen. This in vivo rat brain paradigm provides a means for direct empiric testing of the free drug hypothesis in the in vivo state vis-a-vis conventional in vitro methods such as equilibrium dialysis.
METHODS
Eight samples of cord blood were obtained from three males and five females at term after the cord was clamped. Serum was obtained from six patients with rheumatoid arthritis (all females; 28-65 yr), seven metastatic cancer patients (four females, three males; 27-68 yr), and six healthy subjects (two females, four males; [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Because the rate of injection exceeds the rate of either portal blood flow or carotid blood flow, the injection solution traverses the hepatic and brain microcirculation as a bolus without significant mixing with the circulating rat plasma (20, 21) .
Counts per minute were converted to disintegrations per minute by standard quench corrections and the percent brain uptake index (BUI) and liver uptake index (LUI) were calculated as follows: propranolol BUI or LUI = (3H/'4C dpm) in brain or liver/ (3H/14C dpm) in injectate X 100; lidocaine BUI (27) . Substitution of the values for Er0 and k, and using plotted against the concentration of bovine albumin in the carotid injection solution (observed line). The predicted line was obtained from the product, Et" X (% free), where EO = the extraction in the presence of 0.1 g/100 ml albumin, i.e., when >95% of drug is free, and (percent free) was determined from the law of mass action (see figure) for each albumin (alb) concentration. K,) was determined by equilibrium dialysis at 370C. The double-reciprocal plot provides the (app) K,) as determined from the measurements of albumin-bound (B) drug in vivo in the brain capillary, according to the equation, 1/B = 1 + [KI) (app)](1/alb) (Methods). The equivalence of the K,) (app) in vivo and the absolute K,) in vitro is indicative of the lack of transport of albumin-bound propranolol into brain. propranolol were determined as previously described (20) .
R ESU L TS
The addition of bovine albumin to the carotid injection solution resulted in a decreased brain extraction of [3H]propranolol (Fig. 1) . The concentration of albumin that caused a 50% inhibition of transport, i.e., the apparent (app) KD of albumin binding of propranolol in vivo, was 1.9 g/100 nml or 278 ItM (Fig. 1) . The KD (app) in vivo was not significantly different from the KD of albumin binding of propranolol in vitro, 299±25 ,uM (Fig. 1) . The equivalence of the KD in vitro and the KD (app) in vivo indicates only the free (dialyzable) portion of propranolol is available for transport in the presence of albumin (20) . The effects of adding human orosomucoid to the injection solution are shown in Fig. 2 . Orosomucoid inhibited propranolol transport but to a much lesser extent than that predicted on the basis of the free drug in vitro. The concentration of orosomucoid that resulted in 50% binding in vitro was 3.3±0.1 uM, as opposed to the concentration of protein, 23 AM, which caused a 50% inhibition of propranolol transport in vivo.3 These studies suggested orosomucoid-bound propranolol was available for transport into brain.
The effects of varying serum concentrations of orosomucoid on the first pass extraction of [3H]propranolol by brain was examined using human sera. As shown in Table I (20, 22) . tion (Table II) . However, the effect of high orosomucoid concentrations on the brain extraction was blunted compared with the change in the dialyzable percentage, e.g., the brain extraction decreased only 24% in comparing cord and metastatic cancer serum (Table II) Table III . Large concentrations of orosomocoid, e.g., up to 5 mg/ml (125 MuM), had little to no effect on brain extraction of lidocaine but had substantial effects on the free lidocaine in vitro (Table III) . The KD of orosomucoid binding of lidocaine in vitro was 66±5 ,uM, considerably less than the concentration of orosomucoid needed to inhibit brain extraction of lidocaine (Table III) . The effects of human serum on brain extraction of lidocaine was de-
The fact that the (Kr,/n) of albumin binding of lidocaine in vitro (3, Fig. 2 ). However, in the case of lidocaine binding to albumin, the K,, (app) in vivo < (KD/n) in vitro (Fig. 3) , and the physical basis to this discrepancy is unexplained. Possibly the n value, i.e., the number of drug binding sites on albumin, is much greater in vivo than in vitro. The reliability of our estimate of the bovine albumin KD for lidocaine in vitro is supported by the fact that our lidocaine dialysis data are quantitatively similar to those of Routledge et al. (37) for human albumin binding of lidocaine. creased only 16% in comparing cord and metastatic cancer sera (Table II) . The effects of albumin and human serum on the rat liver extraction of propranolol and lidocaine are shown in Table IV . Drug bound either to albumin or to human serum proteins was freely transported into liver.
The 1-octanol/Ringer's partition coefficients for lidocaine and propranolol were 54±2 and 19±1, respectively. DISCUSSION These studies show that albumin-bound drugs, such as propranolol or lidocaine, are not transported through the BBB, but globulin (orosomucoid)-bound drugs are Data are mean±SE (n = 3-4).
readily available for transport into brain. Since the majority of drug in plasma is bound to orosomucoid (5, 10), the circulating drug that is available for entry into peripheral tissues such as brain is not restricted to the free (dialyzable) moiety but includes the larger protein-bound fraction. Since plasma proteins such as albumin or orosomucoid are not measureably transported across brain capillaries (29) or into liver cells (30) on a single circulatory passage, the transport of protein-bound drugs into tissues represents a process by which the drug is stripped off of the plasma protein by the tissue.5
The observation that protein-bound drugs are transported into brain is not predicted by the "free drug" hypothesis, which states that only the fraction of drug that is free in vitro is available for transport into tissues in vivo. Similarly, our previous findings that proteinbound hormone is transported into brain and into liver were not consistent with the "free hormone" hypothesis (20) (21) (22) . We have proposed the "free intermediate" model to account for the diversity characterizing Owing to very large pores and the absence of a basement membrane in liver microvessels, plasma proteins the size of albumin or orosomucoid enjoy instantaneous distribution into the hepatic interstitial space. Therefore, the rate-limiting membrane lining the plasma compartment in liver is the hepatocyte plasma membrane (38 (Table III) . Although the liver capillary transit time is 10-fold greater than the brain capillary transit time, it is unlikely that the nearly complete transport of albumin-bound drug by liver could be sustained by a drug-albumin dissociation reaction on the order of 1-10 s. The most plausible explanation for the rapid transport of albumin-bound drug into liver is the operation of a receptor-mediated mechanism for the transport of albumin-bound ligands. Other studies provide support for the hypothesis that free fatty acids (34) and bile salts (35) bound to albumin enter liver via a receptor-mediated mechanism.
The probable receptor-mediated transport of albumin-bound drug into liver notwithstanding, it is unlikely that this pathway accounts for the large hepatic first pass extraction of basic lipophilic drugs. As noted above, the KD of orosomucoid binding of propranolol is 100-fold greater than the albumin KD. Since the molar concentration of albumin (-700 ,uM, Table I) is only -20-fold greater than the molar concentration of orosomucoid (-40 ,uM, (36) , it is unlikely that a receptor-mediated mechanism exists for the transport of orosomucoid-bound drug into liver. Therefore, the rapid transport of protein-bound propranolol and lidocaine in human sera into liver (Table III) probably represents transport via the free intermediate mechanism. Finally, the observation of the present study that globulin-bound drug is transported into a peripheral tissue like brain must be reconciled with the clinical practice of using free plasma drug levels to monitor therapy. One view might be that a kinetic approach such as used in the present studies reveals the pathway of drug movement from the circulation into the tissue. However, the kinetics of the transport process may be so fast that equilibrium between the plasma proteins and the permeability barrier, e.g., the endothelial wall, is established within a fraction of the capillary transit time. Therefore, equilibrium measurements of free drug in vitro may underestimate the exchangeable plasma drug in vivo but equilibrium measurements, assuming tissue factors are constant, will still parallel changes in the exchangeable drug in vivo. However, a dialogue is created by an opposing view that considers it unlikely or, at least, unproven, that a new equilibrium between plasma proteins and the endothelial wall is established within a fraction of the transit time. Therefore, equilibrium measurements in vitro will not necessarily parallel the exchangeable drug in vivo (22) . This dialogue and the utility of clinical measurements of free drug levels in plasma will be clarified by future studies, which attempt to reconcile the kinetic and equilibrium descriptions of the exchangeable drug in vivo.
